Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Ex vivo assays to predict enhanced chemosensitization by hyperthermia in urothelial cancer of the bladder.

van den Tempel N, Naipal KAT, Raams A, van Gent DC, Franckena M, Boormans JL, Kanaar R.

PLoS One. 2018 Dec 14;13(12):e0209101. doi: 10.1371/journal.pone.0209101. eCollection 2018.

2.

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients.

de Jong JJ, Hendricksen K, Rosier M, Mostafid H, Boormans JL.

Bladder Cancer. 2018 Oct 29;4(4):395-401. doi: 10.3233/BLC-180191.

3.

Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.

Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, van Kessel KE, Voskuilen CS, Winters B, Erho N, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, Fransen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall'Era M, van der Heijden MS, Wright JL, Black PC.

Clin Cancer Res. 2018 Sep 17. doi: 10.1158/1078-0432.CCR-18-1106. [Epub ahead of print]

PMID:
30224344
4.

Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.

Hermans TJN, Voskuilen CS, Deelen M, Mertens LS, Horenblas S, Meijer RP, Boormans JL, Aben KK, van der Heijden MS, Pos FJ, de Wit R, Beerepoot LV, Verhoeven RHA, van Rhijn BWG.

Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31833. [Epub ahead of print]

PMID:
30155893
5.

ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.

Monteiro LL, Witjes JA, Agarwal PK, Anderson CB, Bivalacqua TJ, Bochner BH, Boormans JL, Chang SS, Domínguez-Escrig JL, McKiernan JM, Dinney C, Godoy G, Kulkarni GS, Mariappan P, O'Donnell MA, Rentsch CA, Shah JB, Solsona E, Svatek RS, van der Heijden AG, van Valenberg FJP, Kassouf W.

World J Urol. 2018 Aug 14. doi: 10.1007/s00345-018-2438-9. [Epub ahead of print] Review.

PMID:
30109483
6.

Total pelvic exenteration for locally advanced and locally recurrent rectal cancer in the elderly.

Hagemans JAW, Rothbarth J, Kirkels WJ, Boormans JL, van Meerten E, Nuyttens JJME, Madsen EVE, Verhoef C, Burger JWA.

Eur J Surg Oncol. 2018 Oct;44(10):1548-1554. doi: 10.1016/j.ejso.2018.06.033. Epub 2018 Jul 20.

PMID:
30075979
7.

Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.

de Jong JJ, Stoop H, Nieboer D, Boormans JL, van Leenders GJLH.

Histopathology. 2018 Dec;73(6):983-989. doi: 10.1111/his.13710. Epub 2018 Sep 25.

PMID:
30003574
8.

Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer.

Fransen van de Putte EE, Otto W, Hartmann A, Bertz S, Mayr R, Bründl J, Breyer J, Manach Q, Compérat EM, Boormans JL, Bosschieter J, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Burger M, van der Kwast TH, van Rhijn BWG.

Urol Oncol. 2018 Aug;36(8):361.e7-361.e13. doi: 10.1016/j.urolonc.2018.05.007. Epub 2018 Jun 5.

PMID:
29880460
9.

Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: The REBACARE-trial.

van Doeveren T, van Leeuwen PJ, Aben KKH, van der Aa M, Barendrecht M, Boevé ER, Cornel EB, van der Heijden AG, Hendricksen K, Hirdes W, Kooistra A, Kroon B, Leliveld AM, Meijer RP, van Melick H, Merks B, de Reijke TM, de Vries P, Wymenga LFA, Wijsman B, Boormans JL.

Contemp Clin Trials Commun. 2018 Feb 28;9:121-129. doi: 10.1016/j.conctc.2018.01.007. eCollection 2018 Mar.

10.

Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy.

Winters BR, Vakar-Lopez F, Brown L, Montgomery B, Seiler R, Black PC, Boormans JL, Dall Era M, Davincioni E, Douglas J, Gibb EA, van Rhijn BWG, van der Heijden MS, Hsieh AC, Wright JL, Lam HM.

Urol Oncol. 2018 Jul;36(7):342.e7-342.e14. doi: 10.1016/j.urolonc.2018.03.016. Epub 2018 Apr 12.

11.

The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer.

van de Putte EEF, Bosschieter J, van der Kwast TH, Bertz S, Denzinger S, Manach Q, Compérat EM, Boormans JL, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Otto W, Burger M, Hartmann A, van Rhijn BWG.

BJU Int. 2018 Dec;122(6):978-985. doi: 10.1111/bju.14238. Epub 2018 Apr 27.

PMID:
29637669
12.

Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network.

Zuiverloon TCM, van Kessel KEM, Bivalacqua TJ, Boormans JL, Ecke TH, Grivas PD, Kiltie AE, Liedberg F, Necchi A, van Rhijn BW, Roghmann F, Sanchez-Carbayo M, Schmitz-Dräger BJ, Wezel F, Kamat AM.

Urol Oncol. 2018 Sep;36(9):423-431. doi: 10.1016/j.urolonc.2018.01.014. Epub 2018 Mar 2. Review.

PMID:
29496372
13.

Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.

van Kessel KEM, van der Keur KA, Dyrskjøt L, Algaba F, Welvaart NYC, Beukers W, Segersten U, Keck B, Maurer T, Simic T, Horstmann M, Grimm MO, Hermann GG, Mogensen K, Hartmann A, Harving N, Petersen AC, Jensen JB, Junker K, Boormans JL, Real FX, Malats N, Malmström PU, Ørntoft TF, Zwarthoff EC.

Clin Cancer Res. 2018 Apr 1;24(7):1586-1593. doi: 10.1158/1078-0432.CCR-17-2719. Epub 2018 Jan 24.

PMID:
29367430
15.

Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel.

Boormans JL, Mayor de Castro J, Marconi L, Yuan Y, Laguna Pes MP, Bokemeyer C, Nicolai N, Algaba F, Oldenburg J, Albers P.

Eur Urol. 2017 Nov 20. pii: S0302-2838(17)30826-6. doi: 10.1016/j.eururo.2017.09.025. [Epub ahead of print] Review.

PMID:
29100813
16.

Heat-induced BRCA2 degradation in human tumours provides rationale for hyperthermia-PARP-inhibitor combination therapies.

van den Tempel N, Odijk H, van Holthe N, Naipal K, Raams A, Eppink B, van Gent DC, Hardillo J, Verduijn GM, Drooger JC, van Rhoon GC, Smedts DHPM, van Doorn HC, Boormans JL, Jager A, Franckena M, Kanaar R.

Int J Hyperthermia. 2018 Jun;34(4):407-414. doi: 10.1080/02656736.2017.1355487. Epub 2017 Jul 31.

PMID:
28705099
17.

Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.

Rijnders M, de Wit R, Boormans JL, Lolkema MPJ, van der Veldt AAM.

Eur Urol. 2017 Sep;72(3):411-423. doi: 10.1016/j.eururo.2017.06.012. Epub 2017 Jun 20. Review.

PMID:
28645491
18.

Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis.

Luchini C, Fleischmann A, Boormans JL, Fassan M, Nottegar A, Lucato P, Stubbs B, Solmi M, Porcaro A, Veronese N, Brunelli M, Scarpa A, Cheng L.

Sci Rep. 2017 May 24;7(1):2374. doi: 10.1038/s41598-017-02577-4. Review.

19.

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC.

Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5.

PMID:
28390739
20.

A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.

van Kessel KE, van de Werken HJ, Lurkin I, Ziel-van der Made AC, Zwarthoff EC, Boormans JL.

PLoS One. 2017 Mar 20;12(3):e0174039. doi: 10.1371/journal.pone.0174039. eCollection 2017.

21.

FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.

Beukers W, van der Keur KA, Kandimalla R, Vergouwe Y, Steyerberg EW, Boormans JL, Jensen JB, Lorente JA, Real FX, Segersten U, Orntoft TF, Malats N, Malmström PU, Dyrskjot L, Zwarthoff EC.

J Urol. 2017 Jun;197(6):1410-1418. doi: 10.1016/j.juro.2016.12.096. Epub 2016 Dec 31.

PMID:
28049011
22.

Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study.

Hermans TJ, Fransen van de Putte EE, Horenblas S, Meijer RP, Boormans JL, Aben KK, van der Heijden MS, de Wit R, Beerepoot LV, Verhoeven RH, van Rhijn BW.

Eur J Cancer. 2016 Dec;69:1-8. doi: 10.1016/j.ejca.2016.09.015. Epub 2016 Oct 27.

PMID:
27814469
23.

Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.

van Kessel KE, Beukers W, Lurkin I, Ziel-van der Made A, van der Keur KA, Boormans JL, Dyrskjøt L, Márquez M, Ørntoft TF, Real FX, Segersten U, Malats N, Malmström PU, Van Criekinge W, Zwarthoff EC.

J Urol. 2017 Mar;197(3 Pt 1):590-595. doi: 10.1016/j.juro.2016.09.118. Epub 2016 Oct 13.

PMID:
27746284
24.

Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder Cancer.

van Kessel KE, de Haan LM, Fransen van de Putte EE, van Rhijn BW, de Wit R, van der Heijden MS, Zwarthoff EC, Boormans JL.

Bladder Cancer. 2016 Jul 27;2(3):351-360.

25.

Limited Funds for Bladder Cancer Research and What Can We Do About It.

Boormans JL, Zwarthoff EC.

Bladder Cancer. 2016 Jan 28;2(1):49-51.

26.

Fractionated high-dose-rate brachytherapy as monotherapy in prostate cancer: Does implant displacement and its correction influence acute and late toxicity?

Aluwini S, Busser WM, Baartman LE, Bhawanie A, Alemayehu WG, Boormans JL, Kolkman-Deurloo IK.

Brachytherapy. 2016 Nov - Dec;15(6):707-713. doi: 10.1016/j.brachy.2016.05.008. Epub 2016 Jun 28.

PMID:
27364871
27.

Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.

Aluwini S, Busser WM, Alemayehu WG, Boormans JL, Kirkels WJ, Jansen PP, Praag JO, Bangma CH, Kolkman-Deurloo IK.

Radiother Oncol. 2015 Nov;117(2):252-7. doi: 10.1016/j.radonc.2015.09.019. Epub 2015 Sep 22.

PMID:
26409832
28.

Targeted therapies in bladder cancer: an overview of in vivo research.

van Kessel KE, Zuiverloon TC, Alberts AR, Boormans JL, Zwarthoff EC.

Nat Rev Urol. 2015 Dec;12(12):681-94. doi: 10.1038/nrurol.2015.231. Epub 2015 Sep 22. Review.

PMID:
26390971
29.

Bladder function preservation with brachytherapy, external beam radiation therapy, and limited surgery in bladder cancer patients: Long-term results [corrected].

Aluwini S, van Rooij PH, Kirkels WJ, Boormans JL, Kolkman-Deurloo IK, Wijnmaalen A.

Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):611-7. doi: 10.1016/j.ijrobp.2013.11.227. Epub 2014 Jan 7. Erratum in: Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):241.

PMID:
24411629
30.

A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers.

Gasi Tandefelt D, Boormans JL, van der Korput HA, Jenster GW, Trapman J.

Eur Urol. 2013 Dec;64(6):941-50. doi: 10.1016/j.eururo.2013.02.039. Epub 2013 Mar 7.

PMID:
23490727
31.

Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.

Boormans JL, Korsten H, Ziel-van der Made AJ, van Leenders GJ, de Vos CV, Jenster G, Trapman J.

Int J Cancer. 2013 Jul 15;133(2):335-45. doi: 10.1002/ijc.28025. Epub 2013 Feb 12.

32.

Down-staging (<pT2) of urothelial cancer at cystectomy after the diagnosis of detrusor muscle invasion (pT2) at diagnostic transurethral resection (TUR): is prediction possible?

Beukers W, Meijer T, Vissers CJ, Boormans JL, Zwarthoff EC, van Leenders GJ.

Virchows Arch. 2012 Aug;461(2):149-56. doi: 10.1007/s00428-012-1277-0. Epub 2012 Jul 10.

33.

Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice.

van Leenders GJ, Boormans JL, Vissers CJ, Hoogland AM, Bressers AA, Furusato B, Trapman J.

Mod Pathol. 2011 Aug;24(8):1128-38. doi: 10.1038/modpathol.2011.65. Epub 2011 Apr 15.

34.

Confirmation of the association of TMPRSS2(exon 0):ERG expression and a favorable prognosis of primary prostate cancer.

Boormans JL, Porkka K, Visakorpi T, Trapman J.

Eur Urol. 2011 Jul;60(1):183-4. doi: 10.1016/j.eururo.2011.03.028. Epub 2011 Mar 29. No abstract available.

PMID:
21474234
35.

No evidence of FGFR3 mutations in prostate cancer.

Zuiverloon TC, Boormans JL, Trapman J, van Leenders GJ, Zwarthoff EC.

Prostate. 2011 May;71(6):637-41. doi: 10.1002/pros.21279. Epub 2010 Oct 18.

PMID:
20957671
36.

E17K substitution in AKT1 in prostate cancer.

Boormans JL, Korsten H, Ziel-van der Made AC, van Leenders GJ, Verhagen PC, Trapman J.

Br J Cancer. 2010 May 11;102(10):1491-4. doi: 10.1038/sj.bjc.6605673. Epub 2010 Apr 20.

37.

Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.

Hermans KG, Boormans JL, Gasi D, van Leenders GJ, Jenster G, Verhagen PC, Trapman J.

Clin Cancer Res. 2009 Oct 15;15(20):6398-403. doi: 10.1158/1078-0432.CCR-09-1176. Epub 2009 Oct 13.

38.

Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naïve, node-positive prostate cancer.

Boormans JL, Hermans KG, Made AC, van Leenders GJ, Wildhagen MF, Collette L, Schröder FH, Trapman J, Verhagen PC.

Eur Urol. 2010 May;57(5):830-5. doi: 10.1016/j.eururo.2009.08.013. Epub 2009 Aug 22.

PMID:
19716227
39.

An activating mutation in AKT1 in human prostate cancer.

Boormans JL, Hermans KG, van Leenders GJ, Trapman J, Verhagen PC.

Int J Cancer. 2008 Dec 1;123(11):2725-6. doi: 10.1002/ijc.23787. No abstract available.

40.

Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer.

Hermans KG, van der Korput HA, van Marion R, van de Wijngaart DJ, Ziel-van der Made A, Dits NF, Boormans JL, van der Kwast TH, van Dekken H, Bangma CH, Korsten H, Kraaij R, Jenster G, Trapman J.

Cancer Res. 2008 Sep 15;68(18):7541-9. doi: 10.1158/0008-5472.CAN-07-5930.

41.

Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.

Boormans JL, Wildhagen MF, Bangma CH, Verhagen PC, van Leenders GJ.

BJU Int. 2008 Dec;102(11):1589-93. doi: 10.1111/j.1464-410X.2008.07904.x. Epub 2008 Aug 14.

42.

Re: Prostate cancer progression and survival in BRCA2 mutation carriers.

Boormans JL, Schröder FH.

Eur Urol. 2007 Nov;52(5):1529. No abstract available.

PMID:
17985426
44.

Carcinoma of the sigmoid presenting as a right inguinal hernia.

Boormans JL, Hesp WL, Teune TM, Plaisier PW.

Hernia. 2006 Mar;10(1):93-6. Epub 2005 Aug 17.

PMID:
16132189
45.

Percutaneous nephrolithotomy for treating renal calculi in children.

Boormans JL, Scheepe JR, Verkoelen CF, Verhagen PC.

BJU Int. 2005 Mar;95(4):631-4.

Supplemental Content

Loading ...
Support Center